Danielle Brill
Stock Analyst at Truist Financial
(4.68)
# 767
Out of 4,355 analysts
374
Total ratings
55%
Success rate
14.2%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Rated: Hold | $81 | $82.14 | -1.39% | 4 | May 28, 2026 | |
| VRTX Vertex Pharmaceuticals | Initiated Coverage: Buy | $542 | $447.54 | +21.11% | 6 | May 27, 2026 | |
| IMVT Immunovant | Maintained: Hold | $23 → $30 | $33.30 | -9.91% | 14 | May 22, 2026 | |
| PVLA Palvella Therapeutics | Maintained: Buy | n/a | $118.46 | - | 12 | May 21, 2026 | |
| WVE Wave Life Sciences | Maintained: Buy | n/a | $6.58 | - | 2 | May 19, 2026 | |
| RAPP Rapport Therapeutics | Maintained: Buy | $56 | $39.50 | +41.77% | 2 | May 19, 2026 | |
| INSM Insmed | Maintained: Buy | $185 | $106.91 | +73.04% | 8 | May 18, 2026 | |
| BIIB Biogen | Maintained: Hold | n/a | $196.00 | - | 17 | May 15, 2026 | |
| UPB Upstream Bio | Maintained: Buy | $43 | $8.36 | +414.35% | 6 | May 14, 2026 | |
| MAZE Maze Therapeutics | Maintained: Buy | n/a | $26.46 | - | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,030 | $835.99 | +23.21% | 30 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $31.17 | +92.52% | 11 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $102 | $66.26 | +53.94% | 14 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $10.96 | +55.11% | 3 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $25 → $29 | $31.59 | -8.20% | 19 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $155 | $158.30 | -2.08% | 21 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 | $93.01 | +18.27% | 6 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 | $69.57 | +19.30% | 16 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $301.98 | - | 13 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $38 | $39.76 | -4.43% | 11 | Apr 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $9.17 | $28.53 | n/a | 23 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $7.01 | n/a | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $21.66 | n/a | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $79 | $57.29 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $150 | $17.87 | n/a | 36 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $73.85 | n/a | 21 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $29.40 | n/a | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $52 → $50 | $54.73 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $21.04 | n/a | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.93 | n/a | 19 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $10 | $5.77 | n/a | 5 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $13.35 | n/a | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $45 | $11.25 | n/a | 2 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $42.19 | n/a | 10 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $234.48 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $5 | $20.65 | n/a | 5 | Nov 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $134.43 | n/a | 1 | Jul 26, 2016 |
Apogee Therapeutics
May 28, 2026
Rated: Hold
Price Target: $81
Current: $82.14
Upside: -1.39%
Vertex Pharmaceuticals
May 27, 2026
Initiated Coverage: Buy
Price Target: $542
Current: $447.54
Upside: +21.11%
Immunovant
May 22, 2026
Maintained: Hold
Price Target: $23 → $30
Current: $33.30
Upside: -9.91%
Palvella Therapeutics
May 21, 2026
Maintained: Buy
Price Target: n/a
Current: $118.46
Upside: -
Wave Life Sciences
May 19, 2026
Maintained: Buy
Price Target: n/a
Current: $6.58
Upside: -
Rapport Therapeutics
May 19, 2026
Maintained: Buy
Price Target: $56
Current: $39.50
Upside: +41.77%
Insmed
May 18, 2026
Maintained: Buy
Price Target: $185
Current: $106.91
Upside: +73.04%
Biogen
May 15, 2026
Maintained: Hold
Price Target: n/a
Current: $196.00
Upside: -
Upstream Bio
May 14, 2026
Maintained: Buy
Price Target: $43
Current: $8.36
Upside: +414.35%
Maze Therapeutics
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $26.46
Upside: -
May 11, 2026
Maintained: Buy
Price Target: $1,030
Current: $835.99
Upside: +23.21%
May 11, 2026
Maintained: Buy
Price Target: $60
Current: $31.17
Upside: +92.52%
May 11, 2026
Reiterated: Buy
Price Target: $102
Current: $66.26
Upside: +53.94%
May 11, 2026
Reiterated: Buy
Price Target: $17
Current: $10.96
Upside: +55.11%
May 8, 2026
Maintained: Hold
Price Target: $25 → $29
Current: $31.59
Upside: -8.20%
May 7, 2026
Rated: Buy
Price Target: $155
Current: $158.30
Upside: -2.08%
May 7, 2026
Maintained: Buy
Price Target: $110
Current: $93.01
Upside: +18.27%
May 6, 2026
Maintained: Buy
Price Target: $83
Current: $69.57
Upside: +19.30%
May 1, 2026
Maintained: Buy
Price Target: n/a
Current: $301.98
Upside: -
Apr 12, 2026
Downgraded: Hold
Price Target: $38
Current: $39.76
Upside: -4.43%
Dec 10, 2024
Maintained: Buy
Price Target: $20 → $9.17
Current: $28.53
Upside: n/a
Nov 18, 2024
Reiterated: Buy
Price Target: $18
Current: $7.01
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $21.66
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $79
Current: $57.29
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $150
Current: $17.87
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $73.85
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $29.40
Upside: n/a
Oct 10, 2024
Initiated Coverage: Buy
Price Target: $52 → $50
Current: $54.73
Upside: n/a
Oct 10, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $21.04
Upside: n/a
Jun 26, 2023
Downgraded: Hold
Price Target: n/a
Current: $6.93
Upside: n/a
May 16, 2022
Maintained: Buy
Price Target: $24 → $10
Current: $5.77
Upside: n/a
Jun 30, 2021
Initiated Coverage: Hold
Price Target: n/a
Current: $13.35
Upside: n/a
May 27, 2020
Maintained: Buy
Price Target: $35 → $45
Current: $11.25
Upside: n/a
Feb 13, 2020
Maintained: Hold
Price Target: n/a
Current: $42.19
Upside: n/a
Dec 16, 2019
Reiterated: Buy
Price Target: $125
Current: $234.48
Upside: n/a
Nov 7, 2019
Maintained: Hold
Price Target: $6 → $5
Current: $20.65
Upside: n/a
Jul 26, 2016
Downgraded: Hold
Price Target: n/a
Current: $134.43
Upside: n/a